185 related articles for article (PubMed ID: 38098086)
21. Prognostic implications of lobular breast cancer histology: new insights from a single hospital cross-sectional study and SEER data.
Brouckaert O; Laenen A; Smeets A; Christiaens MR; Vergote I; Wildiers H; Moerman P; Floris G; Neven P;
Breast; 2014 Aug; 23(4):371-7. PubMed ID: 24530094
[TBL] [Abstract][Full Text] [Related]
22. Deciphering the Clinical Behaviour of Invasive Lobular Carcinoma of the Breast Defines an Aggressive Subtype.
Makhlouf S; Atallah NM; Polotto S; Lee AHS; Green AR; Rakha EA
Cancers (Basel); 2024 May; 16(10):. PubMed ID: 38791971
[TBL] [Abstract][Full Text] [Related]
23. Classifying invasive lobular carcinoma as special type breast cancer may be reducing its treatment success: A comparison of survival among invasive lobular carcinoma, invasive ductal carcinoma, and no-lobular special type breast cancer.
Cosar R; Sut N; Topaloglu S; Tastekin E; Nurlu D; Ozler T; Şenödeyici E; Dedeli M; Chousein M; Cicin I
PLoS One; 2023; 18(7):e0283445. PubMed ID: 37428725
[TBL] [Abstract][Full Text] [Related]
24. The impact of histologic subtype on primary site surgery in the management of metastatic lobular versus ductal breast cancer: a population based study from the National Cancer Database (NCDB).
Rothschild HT; Clelland EN; Abel MK; Chien AJ; Shui AM; Esserman L; Khan SA; Mukhtar RA
Breast Cancer Res Treat; 2024 Jan; 203(2):245-256. PubMed ID: 37833450
[TBL] [Abstract][Full Text] [Related]
25. The effect of (neo)adjuvant chemotherapy on long-term survival outcomes in patients with invasive lobular breast cancer treated with endocrine therapy: A retrospective cohort study.
Öztekin S; Hooning MJ; van Deurzen CHM; Dietvorst AHP; Drooger JC; Kitzen JJEM; Martens JWM; van der Padt-Pruijsten A; Vastbinder MB; Zuetenhorst H; Heemskerk-Gerritsen BAM; Jager A
Cancer; 2024 Mar; 130(6):927-935. PubMed ID: 37985357
[TBL] [Abstract][Full Text] [Related]
26. Infiltrating lobular carcinoma. Is it different from infiltrating duct carcinoma?
Silverstein MJ; Lewinsky BS; Waisman JR; Gierson ED; Colburn WJ; Senofsky GM; Gamagami P
Cancer; 1994 Mar; 73(6):1673-7. PubMed ID: 8156495
[TBL] [Abstract][Full Text] [Related]
27. Canonical Kaiso target genes define a functional signature that associates with breast cancer survival and the invasive lobular carcinoma histological type.
Sijnesael T; Richard F; Rätze MA; Koorman T; Bassey-Archibong B; Rohof C; Daniel J; Desmedt C; Derksen PW
J Pathol; 2023 Dec; 261(4):477-489. PubMed ID: 37737015
[TBL] [Abstract][Full Text] [Related]
28. Expression of cancer-associated fibroblast-related proteins differs between invasive lobular carcinoma and invasive ductal carcinoma.
Park CK; Jung WH; Koo JS
Breast Cancer Res Treat; 2016 Aug; 159(1):55-69. PubMed ID: 27469595
[TBL] [Abstract][Full Text] [Related]
29. Axillary lymph node status and invasive lobular breast cancer : Analysis of the Clinical Tumor Register of the AGO Austria.
Danzinger S; Pöckl K; Kronawetter G; Pfeifer C; Behrendt S; Gscheidlinger P; Harrasser L; Mühlböck H; Dirschlmayer W; Schauer C; Reitsamer R; Uher H; Schönau K; Delmarko I; Singer CF
Wien Klin Wochenschr; 2023 Sep; 135(17-18):463-471. PubMed ID: 37010596
[TBL] [Abstract][Full Text] [Related]
30. Survival analysis in patients with invasive lobular cancer and invasive ductal cancer according to hormone receptor expression status in the Korean population.
Kwon D; Ko BK; Jung SP; Kim HK; Kim EK; Jung YS; Youn HJ; Lee SB
PLoS One; 2022; 17(1):e0262709. PubMed ID: 35051228
[TBL] [Abstract][Full Text] [Related]
31. Magnitude of trastuzumab benefit in patients with HER2-positive, invasive lobular breast carcinoma: results from the HERA trial.
Metzger-Filho O; Procter M; de Azambuja E; Leyland-Jones B; Gelber RD; Dowsett M; Loi S; Saini KS; Cameron D; Untch M; Smith I; Gianni L; Baselga J; Jackisch C; Bell R; Sotiriou C; Viale G; Piccart-Gebhart M
J Clin Oncol; 2013 Jun; 31(16):1954-60. PubMed ID: 23589556
[TBL] [Abstract][Full Text] [Related]
32. Comparison of the clinicopathological features of invasive ductal, invasive lobular, and mixed (invasive ductal + invasive lobular) carcinoma of the breast.
Zengel B; Yararbas U; Duran A; Uslu A; Elıyatkın N; Demırkıran MA; Cengiz F; Şimşek C; Postacı H; Vardar E; Durusoy R
Breast Cancer; 2015 Jul; 22(4):374-81. PubMed ID: 23925582
[TBL] [Abstract][Full Text] [Related]
33. Diffuse invasive breast carcinoma of no special type.
Tot T
Virchows Arch; 2016 Feb; 468(2):199-206. PubMed ID: 26521062
[TBL] [Abstract][Full Text] [Related]
34. Management of the axilla in breast cancer: outcome analysis in a series of ductal versus lobular invasive cancers.
Corona SP; Bortul M; Scomersi S; Bigal C; Bottin C; Zanconati F; Fox SB; Giudici F; Generali D
Breast Cancer Res Treat; 2020 Apr; 180(3):735-745. PubMed ID: 32060782
[TBL] [Abstract][Full Text] [Related]
35. Invasive Pleomorphic Lobular Histology Is an Adverse Prognostic Factor on Survival in Patients with Breast Cancer.
Sahin S; Karatas F; Erdem GU; Hacioglu B; Altundag K
Am Surg; 2017 Apr; 83(4):359-364. PubMed ID: 28424130
[TBL] [Abstract][Full Text] [Related]
36. Invasive lobular carcinoma of the breast: response to hormonal therapy and outcomes.
Rakha EA; El-Sayed ME; Powe DG; Green AR; Habashy H; Grainge MJ; Robertson JF; Blamey R; Gee J; Nicholson RI; Lee AH; Ellis IO
Eur J Cancer; 2008 Jan; 44(1):73-83. PubMed ID: 18035533
[TBL] [Abstract][Full Text] [Related]
37. The role of histological subtype in hormone receptor positive metastatic breast cancer: similar survival but different therapeutic approaches.
Lobbezoo D; Truin W; Voogd A; Roumen R; Vreugdenhil G; Dercksen MW; van den Berkmortel F; Smilde T; van de Wouw A; van Kampen R; van Riel J; Peters N; Peer P; Tjan-Heijnen VC
Oncotarget; 2016 May; 7(20):29412-9. PubMed ID: 27121067
[TBL] [Abstract][Full Text] [Related]
38. HER-2 low status in early-stage invasive lobular carcinoma of the breast: associated factors and outcomes in an institutional series.
Rothschild HT; Clelland E; Patterson A; Molina-Vega J; Kaur M; Symmans WF; Schwartz CJ; Chien AJ; Mukhtar RA
Breast Cancer Res Treat; 2023 Jun; 199(2):349-354. PubMed ID: 37017812
[TBL] [Abstract][Full Text] [Related]
39. The Yale University experience of early-stage invasive lobular carcinoma (ILC) and invasive ductal carcinoma (IDC) treated with breast conservation treatment (BCT): analysis of clinical-pathologic features, long-term outcomes, and molecular expression of COX-2, Bcl-2, and p53 as a function of histology.
Moran MS; Yang Q; Haffty BG
Breast J; 2009; 15(6):571-8. PubMed ID: 19995377
[TBL] [Abstract][Full Text] [Related]
40. Current and future diagnostic and treatment strategies for patients with invasive lobular breast cancer.
Van Baelen K; Geukens T; Maetens M; Tjan-Heijnen V; Lord CJ; Linn S; Bidard FC; Richard F; Yang WW; Steele RE; Pettitt SJ; Van Ongeval C; De Schepper M; Isnaldi E; Nevelsteen I; Smeets A; Punie K; Voorwerk L; Wildiers H; Floris G; Vincent-Salomon A; Derksen PWB; Neven P; Senkus E; Sawyer E; Kok M; Desmedt C
Ann Oncol; 2022 Aug; 33(8):769-785. PubMed ID: 35605746
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
